Trips, Pharmaceutical Innovation and Access to Medicines

Mario Villarreal and Elizabeth DuPre
Additional contact information
Mario Villarreal: American Enterprise Institute
Elizabeth DuPre: American Enterprise Institute

Chapter Chapter 10 in Innovation, Employment and Growth Policy Issues in the EU and the US, 2009, pp 189-205 from Springer

Abstract: In the late 1970s, creative minds began harnessing the power of genetics and molecular biology to fuel an emerging revolution in drug development. Ever since, pharmaceutical innovations have been prolonging human life and alleviating human suffering, by treating what were once intractable diseases and medical conditions. In the years ahead, patients will likely benefit further from a growing arsenal of precision-guided weapons that more effectively target the lifelines of disease while minimizing the collateral damage of side effects.

Keywords: Foreign Direct Investment; Intellectual Property; Patent System; Compulsory License; Trips Agreement (search for similar items in EconPapers)
Date: 2009
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-642-00631-9_10

Ordering information: This item can be ordered from
http://www.springer.com/9783642006319

DOI: 10.1007/978-3-642-00631-9_10

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().